NCCN patient guidelines listed among top global sources for trustworthy online information

April 20, 2020

PLYMOUTH MEETING, PA [April 20, 2020] -- A recently-published study from researchers in Australia and South Africa found the NCCN Guidelines for Patients to be among the most trustworthy resources for patients and caregivers seeking information online about prostate cancer. The independent, peer-reviewed international study published in Current Urology examined the top 90 English-language Google results for medical information on prostate cancer, and measured reliability and transparency according to Journal of American Medical Association (JAMA) benchmarks and DISCERN criteria from the Division of Public Health and Primary Care at Oxford University. The NCCN Guidelines for Patients received highest rankings in both.

"We publish the NCCN Guidelines for Patients so people with cancer and their caregivers have access to the same information as their doctors, including the latest evidence and expert consensus on the best ways to manage their cancer," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "This knowledge is intended to empower people with cancer to take an active role in shared decision-making, ensuring their treatment plan is truly patient-centered."

The NCCN Guidelines for Patients are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), which are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The patient guidelines are written in an easy-to-learn format and include a glossary of medical terms and suggested questions to ask during appointments. The books are available for free digital download at NCCN.org/patients or via the NCCN Patient Guides for Cancer App, with printed versions available for a nominal fee at Amazon.com. Funding for the NCCN Guidelines for Patients comes from the NCCN Foundation and its generous donors. The NCCN Foundation also collaborates with more than 100 patient advocacy groups to help deliver this vital information to patients and families.

"The NCCN Guidelines for Patients: Prostate Cancer outlines essential information about diagnosis and treatment in a comprehensible format. It serves as a foundation of knowledge as patients and families begin to discuss options with their health care provider," according to the Prostate Cancer Foundation (PCF), one of ten organizations to endorse the book, along with California Prostate Cancer Coalition (CPCC), Malecare Cancer Support, National Alliance of State Prostate Cancer Coalitions (NASPCC), National Prostate Cancer Awareness Foundation (PCaAware), Prostate Health Education Network (PHEN), Urology Care Foundation, Us TOO International Prostate Cancer Education and Support Network, Veterans Prostate Cancer Awareness, and ZERO - The End of Prostate Cancer.

In the Current Urology study, the researchers found NCCN's patient information site met all four criteria for validating the quality of information it contained according to the JAMA benchmarks--one of only 15 websites to do so. Additionally, the evaluation based on the DISCERN criteria gave NCCN a score of 76 out of 80, making it the highest ranked site of the first 90 Google search results.

"These patient guidelines are intended to augment, but not replace the information patients get from their physician," said Marcie Reeder, MPH, Executive Director, NCCN Foundation. "It can be difficult to understand complicated medical details at any time, and especially when your mind is reeling after getting a cancer diagnosis. These books give people the opportunity to absorb what's happening to them and mentally prepare at their own pace. With so many people relying on the internet for health information, we're proud to offer something that's been independently validated as reliable and trustworthy. No matter where people receive their care, they can advocate for the latest and best options currently available."

In response to the ongoing Coronavirus Disease 2019 (COVID-19) pandemic, NCCN is also helping to share essential information from NCCN Member Institutions on how to continue providing safe, optimal cancer care under current conditions. Visit NCCN.org/covid-19 for a growing list of free, downloadable resources for patients, providers, and caregivers, including a factsheet for cancer patients and tips for self-care and stress management.

The patient guidelines site had approximately 900,000 unique visitors from all over the world in 2019. Visit NCCN.org/patients to learn more or make a donation to the NCCN Foundation to support essential resources for people with cancer.
-end-
About the NCCN Foundation

The NCCN Foundation was founded by the National Comprehensive Cancer Network (NCCN) to empower people with cancer and advance oncology innovation. The NCCN Foundation empowers people with cancer and their caregivers by delivering unbiased expert guidance from the world's leading cancer experts through the library of NCCN Guidelines for Patients and other patient education resources. The NCCN Foundation is also committed to advancing cancer treatment by funding the nation's promising young investigators at the forefront of cancer research. For more information about the NCCN Foundation, visit NCCN.org/patients.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news. Follow NCCN on Twitter @NCCN, Facebook @NCCNorg, and Instagram @NCCNorg.

National Comprehensive Cancer Network

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.